• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助化疗(NAC)治疗下大型局部晚期乳腺癌患者引流腋窝淋巴结中的肿瘤:免疫细胞(效应细胞、调节细胞)和细胞因子(Th1、Th2)对 NAC 诱导的免疫介导的肿瘤细胞死亡的关键作用。

Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.

机构信息

Division of Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, Faculty of Medicine and Health Sciences, University of Nottingham, E Floor West Block, Queen's Medical Centre, Derby Rd, Nottingham, NG7 2UH, UK.

Department of Surgery, Phramongkutklao Hospital and College of Medicine, 315 Rajavithi Road, Bangkok, 10400, Thailand.

出版信息

BMC Cancer. 2018 Feb 2;18(1):123. doi: 10.1186/s12885-018-4044-z.

DOI:10.1186/s12885-018-4044-z
PMID:29390966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5795830/
Abstract

BACKGROUND

The tumour microenvironment consists of malignant cells, stroma and immune cells. In women with large and locally advanced breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC), tumour-infiltrating lymphocytes (TILs), various subsets (effector, regulatory) and cytokines in the primary tumour play a key role in the induction of tumour cell death and a pathological complete response (pCR) with NAC. Their contribution to a pCR in nodal metastases, however, is poorly studied and was investigated.

METHODS

Axillary lymph nodes (ALNs) (24 with and 9 without metastases) from women with LLABCs undergoing NAC were immunohistochemically assessed for TILs, T effector and regulatory cell subsets, NK cells and cytokine expression using labelled antibodies, employing established semi-quantitative methods. IBM SPSS statistical package (21v) was used. Non-parametric (paired and unpaired) statistical analyses were performed. Univariate and multivariate regression analyses were carried out to establish the prediction of a pCR and Spearman's Correlation Coefficient was used to determine the correlation of immune cell infiltrates in ALN metastatic and primary breast tumours.

RESULTS

In ALN metastases high levels of TILs, CD4 and CD8 T and CD56 NK cells were significantly associated with pCRs.. Significantly higher levels of Tregs (FOXP3, CTLA-4) and CD56 NK cells were documented in ALN metastases than in the corresponding primary breast tumours. CD8 T and CD56 NK cells showed a positive correlation between metastatic and primary tumours. A high % CD8 and low % FOXP3 T cells and high CD8: FOXP3 ratio in metastatic ALNs (tumour-free para-cortex) were associated with pCRs. Metastatic ALNs expressed high IL-10, low IL-2 and IFN-ϒ.

CONCLUSIONS

Our study has provided new data characterising the possible contribution of T effector and regulatory cells and NK cells and T helper1 and 2 cytokines to tumour cell death associated with NAC in ALNs.

TRIAL REGISTRATION

The Trial was retrospectively registered. Study Registration Number is ISRCTN00407556 .

摘要

背景

肿瘤微环境由恶性细胞、基质和免疫细胞组成。在接受新辅助化疗(NAC)的大且局部晚期乳腺癌(LLABC)女性中,原发性肿瘤中的肿瘤浸润淋巴细胞(TIL)、各种亚群(效应、调节)和细胞因子在诱导肿瘤细胞死亡和 NAC 的病理完全缓解(pCR)方面发挥着关键作用。然而,它们对淋巴结转移中 pCR 的贡献研究甚少。

方法

对接受 NAC 的 LLABC 女性的腋窝淋巴结(ALN)(24 个有转移,9 个无转移)进行免疫组织化学评估,使用标记抗体检测 TIL、T 效应和调节细胞亚群、NK 细胞和细胞因子的表达,采用已建立的半定量方法。使用 IBM SPSS 统计软件包(21v)。采用非参数(配对和非配对)统计分析。进行单变量和多变量回归分析以确定 pCR 的预测,并使用 Spearman 相关系数确定 ALN 转移性和原发性乳腺癌中免疫细胞浸润的相关性。

结果

在 ALN 转移中,TIL、CD4 和 CD8 T 以及 CD56 NK 细胞的高水平与 pCR 显著相关。在 ALN 转移中,Tregs(FOXP3、CTLA-4)和 CD56 NK 细胞的水平明显高于相应的原发性乳腺癌。CD8 T 和 CD56 NK 细胞在转移性和原发性肿瘤之间呈正相关。转移性 ALN 中高比例的 CD8 和低比例的 FOXP3 T 细胞以及高 CD8:FOXP3 比值与 pCR 相关。转移性 ALN 表达高 IL-10、低 IL-2 和 IFN-γ。

结论

我们的研究提供了新的数据,这些数据描述了 T 效应和调节细胞、NK 细胞以及辅助性 T 细胞 1 和 2 细胞因子在与 NAC 相关的 ALN 中肿瘤细胞死亡中的可能贡献。

试验注册

该试验是回顾性注册的。研究注册号为 ISRCTN00407556。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/a5051ffd968d/12885_2018_4044_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/a9d8b269d775/12885_2018_4044_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/118f4aff71b9/12885_2018_4044_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/7408b3107d07/12885_2018_4044_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/a5051ffd968d/12885_2018_4044_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/a9d8b269d775/12885_2018_4044_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/118f4aff71b9/12885_2018_4044_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/7408b3107d07/12885_2018_4044_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e15/5795830/a5051ffd968d/12885_2018_4044_Fig4_HTML.jpg

相似文献

1
Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.新辅助化疗(NAC)治疗下大型局部晚期乳腺癌患者引流腋窝淋巴结中的肿瘤:免疫细胞(效应细胞、调节细胞)和细胞因子(Th1、Th2)对 NAC 诱导的免疫介导的肿瘤细胞死亡的关键作用。
BMC Cancer. 2018 Feb 2;18(1):123. doi: 10.1186/s12885-018-4044-z.
2
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.T 淋巴细胞(效应细胞、调节细胞和检查点抑制剂)和细胞因子(TH1、TH2 和 TH17)对新辅助化疗诱导乳腺癌女性病理性完全缓解的重要贡献。
J Immunol Res. 2016;2016:4757405. doi: 10.1155/2016/4757405. Epub 2016 Sep 29.
3
Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.局部晚期乳腺癌(LLABC)女性患者血液和肿瘤中的自然杀伤(NK)细胞特征及其对新辅助化疗(NAC)后肿瘤病理完全缓解(PCR)的贡献:NAC和手术对血液特征的差异恢复作用
J Transl Med. 2015 Jun 4;13:180. doi: 10.1186/s12967-015-0535-8.
4
Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.在接受新辅助化疗(NAC)和手术的大体积局部晚期乳腺癌女性中存在异常调节性 T 细胞(Tregs:FOXP3+,CTLA-4+)、髓系来源抑制细胞(MDSCs:单核细胞、粒细胞)和极化 T 辅助细胞表型(Th1、Th2、Th17):治疗未能消除异常 Treg 表型,Treg 水平与 NAC 病理反应相关。
J Transl Med. 2013 Jan 15;11:16. doi: 10.1186/1479-5876-11-16.
5
The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.新辅助化疗诱导的大型局部晚期乳腺癌患者乳房和腋窝淋巴结良好病理反应中固有免疫系统的差异贡献。
J Immunol Res. 2017;2017:1049023. doi: 10.1155/2017/1049023. Epub 2017 Aug 23.
6
Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.肿瘤浸润淋巴细胞对腋窝淋巴结转移乳腺癌患者新辅助化疗病理反应的预测价值。
Surg Today. 2021 Apr;51(4):595-604. doi: 10.1007/s00595-020-02157-6. Epub 2020 Oct 14.
7
The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.T 细胞浸润的组成在不同分子亚型的原发性浸润性乳腺癌以及根据肿瘤大小和淋巴结状态而有所不同。
Virchows Arch. 2019 Jul;475(1):13-23. doi: 10.1007/s00428-019-02568-y. Epub 2019 Apr 17.
8
Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.新辅助化疗在乳腺癌中不同病理和治疗效果的免疫相关性。
Eur J Surg Oncol. 2020 Jan;46(1):77-84. doi: 10.1016/j.ejso.2019.09.146. Epub 2019 Sep 18.
9
Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.局部晚期乳腺癌的预测和预后因素:肿瘤内 FOXP3+Tregs 的影响。
Clin Exp Metastasis. 2013 Dec;30(8):1047-62. doi: 10.1007/s10585-013-9602-9. Epub 2013 Jul 9.
10
Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.新辅助化疗后前哨淋巴结活检可预测就诊时临床腋窝淋巴结阳性的乳腺癌患者的腋窝病理淋巴结状态。
Int J Clin Oncol. 2013 Jun;18(3):547-53. doi: 10.1007/s10147-012-0418-4. Epub 2012 May 16.

引用本文的文献

1
Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model.在三阴性乳腺癌小鼠模型中通过CTLA-4 siRNA介导的免疫检查点调节增强MUC1 mRNA纳米疫苗的抗肿瘤功效
Int J Mol Sci. 2025 Aug 30;26(17):8448. doi: 10.3390/ijms26178448.
2
Tumor microenvironment and immunotherapy for triple-negative breast cancer.三阴性乳腺癌的肿瘤微环境与免疫治疗
Biomark Res. 2024 Dec 31;12(1):166. doi: 10.1186/s40364-024-00714-6.
3
Present and Future of Immunotherapy for Triple-Negative Breast Cancer.

本文引用的文献

1
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.T 淋巴细胞(效应细胞、调节细胞和检查点抑制剂)和细胞因子(TH1、TH2 和 TH17)对新辅助化疗诱导乳腺癌女性病理性完全缓解的重要贡献。
J Immunol Res. 2016;2016:4757405. doi: 10.1155/2016/4757405. Epub 2016 Sep 29.
2
Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.局部晚期乳腺癌(LLABC)女性患者血液和肿瘤中的自然杀伤(NK)细胞特征及其对新辅助化疗(NAC)后肿瘤病理完全缓解(PCR)的贡献:NAC和手术对血液特征的差异恢复作用
J Transl Med. 2015 Jun 4;13:180. doi: 10.1186/s12967-015-0535-8.
3
三阴性乳腺癌免疫治疗的现状与未来
Cancers (Basel). 2024 Sep 24;16(19):3250. doi: 10.3390/cancers16193250.
4
Advances in immunotherapy for triple-negative breast cancer.三阴性乳腺癌的免疫治疗进展。
Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7.
5
Systemic Profiling of KDM5 Subfamily Signature in Non-Small-Cell Lung Cancer.非小细胞肺癌中KDM5亚家族特征的系统分析
Int J Gen Med. 2021 Oct 27;14:7259-7275. doi: 10.2147/IJGM.S329733. eCollection 2021.
6
Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.化疗使三阴性乳腺癌中 CD8+TNFR2+TILs 的平衡向有利于它们的方向转变。
Cells. 2021 Jun 8;10(6):1429. doi: 10.3390/cells10061429.
7
Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema.将生物学进展融入乳腺癌相关淋巴水肿的临床管理
Front Oncol. 2020 Apr 2;10:422. doi: 10.3389/fonc.2020.00422. eCollection 2020.
8
The role of ubiquitination in tumorigenesis and targeted drug discovery.泛素化在肿瘤发生和靶向药物发现中的作用。
Signal Transduct Target Ther. 2020 Feb 29;5(1):11. doi: 10.1038/s41392-020-0107-0.
9
Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.新辅助化疗后乳腺癌患者肿瘤浸润淋巴细胞及血管正常化的变化及其与无病生存期的相关性
Front Oncol. 2020 Jan 22;9:1545. doi: 10.3389/fonc.2019.01545. eCollection 2019.
Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.患有大型(≥3厘米)局部晚期乳腺癌(T3、4、N1、2、M0)且正在接受新辅助化疗(NAC:环磷酰胺、阿霉素、多西他赛)的女性:添加卡培他滨可提高4年无病生存率。
Springerplus. 2015 Jan 13;4(1):9. doi: 10.1186/2193-1801-4-9. eCollection 2015.
4
Classifying Cancers Based on T-cell Infiltration and PD-L1.基于T细胞浸润和PD-L1对癌症进行分类
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
5
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.肿瘤浸润免疫细胞谱及其在新辅助化疗后的变化可预测乳腺癌的反应和预后。
Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5.
6
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.程序性死亡-1免疫抑制途径:抗肿瘤免疫的障碍。
J Immunol. 2014 Oct 15;193(8):3835-41. doi: 10.4049/jimmunol.1401572.
7
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.2014年国际肿瘤浸润淋巴细胞(TILs)工作组对乳腺癌中肿瘤浸润淋巴细胞的评估建议
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.
8
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.PD-1(+)免疫细胞浸润与可手术乳腺癌患者的生存呈负相关。
Cancer Immunol Immunother. 2014 Apr;63(4):395-406. doi: 10.1007/s00262-014-1519-x. Epub 2014 Feb 11.
9
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌初次化疗后肿瘤浸润淋巴细胞对残留疾病的预后价值:一项回顾性多中心研究
Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8.
10
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.免疫浸润对HER2阴性乳腺癌新辅助化疗反应预测的前瞻性验证——新辅助GeparQuinto试验的一项子研究
PLoS One. 2013 Dec 2;8(12):e79775. doi: 10.1371/journal.pone.0079775. eCollection 2013.